LNA Sante

LNA Sante SA Formerly known as Le Noble Age. LNA Sante SA, formerly known as Le Noble Age SA is a France-based company that owns and operates retirement homes and complexes for elderly residents. The Company's residences provide care and assistance for elderly people with a variety of needs, from those with a high level of independence, to those who are completely dependent. LNA Sante SA is also engaged in real estate operations. The Company has residences in France and Belgium. LNA Sante SA operates through its several subsidiaries, including Le Parc de Diane Sarl, Institut Medicalise de Mar Vivo, Gerhome, Residence le Point du Jour and the home healthcare service provider ARAIR Assistance, as well as ARAIR Group's support and training services, among others.
  • TickerLNA
  • ISINFR0004170017
  • ExchangeEuronext Paris
  • SectorHealth Care Equipment & Services
  • CountryFrance

Analysts

Bruno de La Rochebrochard

LNA SANTÉ: Q3 organic revenue growth accelerating. Recently upgraded FY guidance confirmed | BUY | EUR68

LNA SANTÉ - BUY | EUR68(+47%) Q3 organic revenue growth accelerating. Recently upgraded FY guidance confirmed Sustained Q3 revenue with organic again accelerating Confirmation of FY guidance, revised upwards after H1 results

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Harold De Decker
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Léopold Authié
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 11/07/2018

...

Christophe-Raphaël Ganet

LNA Santé : Solid Q3 2018 revenues (5.1% l-f-l) confirming the guidance for full-year growth of over 4% l-f-l

>Q3: +5.1% organic, slightly better thanks to home care in particular - Q3 operating revenues came to € 110.2m, up 6.4% (+5.1% at constant scope with +2.3% for volumes, +2.8% from the price-mix and 1.3% from acquisitions). LNA did not see any significant openings in Q3.In the first nine months, revenues came to € 324.3m, an increase of 5.5% versus 2017, with 4.4% organic growth.Facilities at cruising speed represent 6,163 beds, or 85% of the total in operati...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Harold De Decker
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Léopold Authié
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 07/11/2018

...

Christophe-Raphaël Ganet

LNA Santé : CA T3 2018 solide (5,1% lfl.) validant la guidance annuelle à plus de 4% lfl.

>T3: +5,1% organique, un peu meilleure grâce à l’HAD notamment - Le CA Exploitation du T3 s’est monté à 110,2 M€, en hausse de 6,4% (+5,1% à pc. dont +2,3% volume et +2,8% de prix-mix et 1,3% de croissance externe). Au T3, LNA n’a pas connu de mouvement d’ouverture significatif.Sur les 9 premiers mois, le CA s'établit à 324,3 M€, en progression de 5,5% par rapport à 2017, dont 4,4% organique.Les établissements en régime de croisière représentent 6 163 lits, ...

Bruno de La Rochebrochard

LNA Santé: Q2 revenue: Ahead our expectation with sustained organic. FY organic now expected over 4%.

Brief Comment - LNA Santé: (BUY, Fair Value EUR68 (+24%)) Q2 revenue: Ahead our expectation with sustained organic. FY organic now expected over 4%.

Bruno de La Rochebrochard

LNA SANTÉ: Q3 organic revenue growth accelerating. Recently upgraded FY guidance confirmed | BUY | EUR68

LNA SANTÉ - BUY | EUR68(+47%) Q3 organic revenue growth accelerating. Recently upgraded FY guidance confirmed Sustained Q3 revenue with organic again accelerating Confirmation of FY guidance, revised upwards after H1 results

Christophe-Raphaël Ganet

LNA Santé : Solid Q3 2018 revenues (5.1% l-f-l) confirming the guidance for full-year growth of over 4% l-f-l

>Q3: +5.1% organic, slightly better thanks to home care in particular - Q3 operating revenues came to € 110.2m, up 6.4% (+5.1% at constant scope with +2.3% for volumes, +2.8% from the price-mix and 1.3% from acquisitions). LNA did not see any significant openings in Q3.In the first nine months, revenues came to € 324.3m, an increase of 5.5% versus 2017, with 4.4% organic growth.Facilities at cruising speed represent 6,163 beds, or 85% of the total in operati...

Christophe-Raphaël Ganet

LNA Santé : CA T3 2018 solide (5,1% lfl.) validant la guidance annuelle à plus de 4% lfl.

>T3: +5,1% organique, un peu meilleure grâce à l’HAD notamment - Le CA Exploitation du T3 s’est monté à 110,2 M€, en hausse de 6,4% (+5,1% à pc. dont +2,3% volume et +2,8% de prix-mix et 1,3% de croissance externe). Au T3, LNA n’a pas connu de mouvement d’ouverture significatif.Sur les 9 premiers mois, le CA s'établit à 324,3 M€, en progression de 5,5% par rapport à 2017, dont 4,4% organique.Les établissements en régime de croisière représentent 6 163 lits, ...

Christophe-Raphaël Ganet

ODDO : Q3 2018 previews: expensive healthcare

>T3: +9.7%e forecast - After growth of around +10% in H1, our forecasts are for growth in the region of 9.7% in Q3.Growth levels are fairly disparate but we can say that the most robust growth levels will likely come from Ipsen, Sartorius Stedim Biotech and bioMérieux. The weakest growth levels will probably be generated by Guerbet, Boiron and Vétoquinol.Virbac has already reported its Q3 results, these were towards the upper end of the forecast range. Q3 pu...

Christophe-Raphaël Ganet

ODDO : Previews T3 2018: chère Santé

>T3: +9.7%e attendus - Après un CA S1 ressortant à environ +10%, nos projections tablent sur une croissance de 9.7%e au T3.Les niveaux de croissance sont assez disparates mais on peut dire que les plus fortes croissances organiques proviendront d’Ipsen, Sartorius Stedim Biotech et bioMérieux. Les plus faibles devraient être publiés par Guerbet, Boiron et Vétoquinol.Le T3 de Virbac a déjà été publié, il était plutôt dans le haut de fourchette des attentes. Le...

1 director sold

A director at Lna Sante Sa sold 500 shares at 55.178EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Harold De Decker
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Léopold Authié
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 11/07/2018

...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Harold De Decker
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Léopold Authié
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 07/11/2018

...

Alex Koagne ...
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Jean Sassus
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/15/2018

...

Ahmed Ben Salem ...
  • Bruno Cavalier
  • Christophe-Raphaël Ganet
  • Emira Sagaama
  • Jean Sassus
  • Laure Billoret
  • Matthias Desmarais
  • Steven Gould
  • Valentin Pernet
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 15/10/2018

...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 20/06/2018

Parmi les résolutions proposées par la société, six portent sur la rémunération des dirigeants. Même si les montants indiqués semblentraisonnables, l'absence de communication du bonus annuel total ne nous permet pas de les soutenir (résolutions 10 à 15). En raison de montants demandés trop élevés et de la possibilité d'utilisation en période d'o?re publique, la majorité des autorisations d'augmentation de capital demandées sera refusée (résolutions 18 à 21 et 23 et 24).

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch